2024
Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerFollicular-derived thyroid cancersAdvanced thyroid cancerThyroid cancerFood and Drug AdministrationManagement of advanced thyroid cancerEra of immunotherapyTargeted kinase inhibitorsU.S Food and Drug AdministrationImmune milieuRefractory diseaseExcellent prognosisTherapeutic optionsTreatment optionsKinase inhibitorsDrug AdministrationGenetic driversTherapeutic avenuesCancerImmunotherapyGenetic landscapeRadioiodineTreatmentMolecular basisOptions
2021
Cancer Immunology and the Evolution of Immunotherapy
Nurieva R, Divenko M, Kim S. Cancer Immunology and the Evolution of Immunotherapy. 2021, 3-29. DOI: 10.1007/978-3-030-56824-5_1.Peer-Reviewed Original ResearchDevelopment of cancer immunotherapeuticsHost anti-tumor immunityCancer immunotherapy modalitiesEvolution of immunotherapyAnti-tumor immunityHost immune cellsImmunotherapy modalitiesCancer immunotherapyCancer immunotherapeuticsCancer immunologyImmune cellsTumor cellsCellular mechanisms of interactionCancer cellsCancerCellular mechanismsImmunotherapyCellsImmunotherapeuticsTumorImmunityImmunologyFDAModalitiesTrials